225 related articles for article (PubMed ID: 29395837)
1. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Hari P; Romanus D; Palumbo A; Luptakova K; Rifkin RM; Tran LM; Raju A; Farrelly E; Noga SJ; Blazer M; Chari A
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):152-160. PubMed ID: 29395837
[TBL] [Abstract][Full Text] [Related]
2. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant.
Ailawadhi S; Ogbonnaya A; Murty S; Cherepanov D; Schroader BK; Romanus D; Farrelly E; Chari A
Cancer Med; 2023 Feb; 12(3):3145-3159. PubMed ID: 36151787
[TBL] [Abstract][Full Text] [Related]
3. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
5. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies.
Hari P; Romanus D; Luptakova K; Blazer M; Yong C; Raju A; Farrelly E; Labotka R; Morrison VA
J Geriatr Oncol; 2018 Mar; 9(2):138-144. PubMed ID: 29056336
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
Chari A; Romanus D; DasMahapatra P; Hoole M; Lowe M; Curran C; Campbell S; Bell JA
Oncologist; 2019 Nov; 24(11):1479-1487. PubMed ID: 31371520
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
10. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
[TBL] [Abstract][Full Text] [Related]
12. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Joffe E; Goldschmidt N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Arad A; Polliack A; Herishanu Y;
Eur J Haematol; 2018 Sep; 101(3):399-406. PubMed ID: 29949186
[TBL] [Abstract][Full Text] [Related]
18. Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Kaneko H; Yagi H; Shibayama H; Tanaka H; Kosugi S; Uoshima N; Kobayashi M; Adachi Y; Ohta K; Ishii K; Uchiyama H; Matsuda M; Nakatani E; Tsudo M; Shimazaki C; Takaori-Kondo A; Nomura S; Matsumura I; Taniwaki M; Kanakura Y;
Int J Hematol; 2015 Jan; 101(1):37-45. PubMed ID: 25385278
[TBL] [Abstract][Full Text] [Related]
19. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
20. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
San-Miguel JF; Dimopoulos MA; Stadtmauer EA; Rajkumar SV; Siegel D; Bravo ML; Olesnyckyj M; Knight RD; Zeldis JB; Harousseau JL; Weber DM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):38-43. PubMed ID: 21273172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
